218 related articles for article (PubMed ID: 31029516)
1. Comparison of the immunogenicity of Dukoral® oral cholera vaccine between renal transplant recipients on either a calcineurin inhibitor or mycophenolate - A controlled trial.
Jonker EFF; Uijlings MAC; Visser LG; Soonawala D
Vaccine; 2019 May; 37(23):3133-3139. PubMed ID: 31029516
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45.
McCarty JM; Lock MD; Hunt KM; Simon JK; Gurwith M
Vaccine; 2018 Feb; 36(6):833-840. PubMed ID: 29317118
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator.
Sow SO; Tapia MD; Chen WH; Haidara FC; Kotloff KL; Pasetti MF; Blackwelder WC; Traoré A; Tamboura B; Doumbia M; Diallo F; Coulibaly F; Onwuchekwa U; Kodio M; Tennant SM; Reymann M; Lam DF; Gurwith M; Lock M; Yonker T; Smith J; Simon JK; Levine MM
Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021299
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
[TBL] [Abstract][Full Text] [Related]
5. A comparison of mycophenolate mofetil and calcineurin inhibitor as maintenance immunosuppression for kidney transplant recipients: A meta-analysis of randomized controlled trials.
Deng J; Lu Y; He L; Ou J; Xie H
Turk J Med Sci; 2021 Jun; 51(3):1080-1091. PubMed ID: 33356028
[TBL] [Abstract][Full Text] [Related]
6. Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial.
McCarty JM; Lock MD; Bennett S; Hunt KM; Simon JK; Gurwith M
Vaccine; 2019 Mar; 37(11):1389-1397. PubMed ID: 30772070
[TBL] [Abstract][Full Text] [Related]
7. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children.
Taylor DN; Cárdenas V; Perez J; Puga R; Svennerholm AM
Am J Trop Med Hyg; 1999 Dec; 61(6):869-73. PubMed ID: 10674661
[TBL] [Abstract][Full Text] [Related]
8. A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.
Russo P; Ligsay AD; Olveda R; Choi SK; Kim DR; Park JY; Park JY; Syed KA; Dey A; Kim YH; Lee SH; Kim J; Chon Y; Digilio L; Kim CW; Excler JL
Vaccine; 2018 Jul; 36(29):4317-4324. PubMed ID: 29895500
[TBL] [Abstract][Full Text] [Related]
9. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
10. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
11. Vaccine specific immune response to an inactivated oral cholera vaccine and EPI vaccines in a high and low arsenic area in Bangladeshi children.
Saha A; Chowdhury MI; Nazim M; Alam MM; Ahmed T; Hossain MB; Hore SK; Sultana GN; Svennerholm AM; Qadri F
Vaccine; 2013 Jan; 31(4):647-52. PubMed ID: 23200936
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines.
Capeding MRZ; Gonzales MLAM; Dhingra MS; D'Cor NA; Midde VJ; Patnaik BN; Thollot Y; Desauziers E
Hum Vaccin Immunother; 2017 Oct; 13(10):2232-2239. PubMed ID: 28910563
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks.
Chen WH; Greenberg RN; Pasetti MF; Livio S; Lock M; Gurwith M; Levine MM
Clin Vaccine Immunol; 2014 Jan; 21(1):66-73. PubMed ID: 24173028
[TBL] [Abstract][Full Text] [Related]
15. Cholera toxin and O-specific polysaccharide immune responses after oral cholera vaccination with Dukoral in different age groups of Bangladeshi participants.
Dash P; Hakim A; Akter A; Banna HA; Kaisar MH; Aktar A; Jahan SR; Ferdous J; Basher SR; Kamruzzaman M; Chowdhury F; Akter A; Tauheed I; Weil AA; Charles RC; Calderwood SB; Ryan ET; LaRocque RC; Harris JB; Bhuiyan TR; Qadri F
mSphere; 2024 Mar; 9(3):e0056523. PubMed ID: 38391226
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults.
Valera R; García HM; Jidy MD; Mirabal M; Armesto MI; Fando R; García L; Fernández R; Año G; Cedré B; Ramírez M; Bravo L; Serrano T; Palma S; González D; Miralles F; Medina V; Nuñez F; Plasencia Y; Martínez JC; Mandarioti A; Lugones J; Rodríguez BL; Moreno A; González D; Baro M; Solis RL; Sierra G; Barbera R; Domínguez F; Gutiérrez C; Kouri G; Campa C; Menéndez J
Vaccine; 2009 Nov; 27(47):6564-9. PubMed ID: 19720365
[TBL] [Abstract][Full Text] [Related]
17. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
[TBL] [Abstract][Full Text] [Related]
19. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.
Perry RT; Plowe CV; Koumaré B; Bougoudogo F; Kotloff KL; Losonsky GA; Wasserman SS; Levine MM
Bull World Health Organ; 1998; 76(1):63-71. PubMed ID: 9615498
[TBL] [Abstract][Full Text] [Related]
20. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]